BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives
BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $19 Price Target
BrainsWay, Inland Psychiatric Collaborate On Multi-System Deep TMS Deployment And Mental Health Research Initiatives
BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives
BrainsWay: Execution Isn't The Problem, Market Size Is
BrainsWay’s (BWAY) Growth Streak Just Got Harder To Ignore
BTIG Reiterates Buy on BrainsWay, Maintains $20 Price Target
Are Options Traders Betting on a Big Move in Brainsway Stock?
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™
HC Wainwright & Co. Maintains Buy on BrainsWay, Raises Price Target to $19
Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation
Brainsway (BWAY) Upgraded to Buy: Here's Why
BrainsWay: Market Saturation And Competition Could Be Issues
Ladenburg Thalmann Maintains Buy on BrainsWay, Raises Price Target to $18.8
Brainsway Q2 Earnings Call Highlights
BrainsWay Ltd (BRSYF) (Q2 2026) Earnings Call Highlights: Revenue Surges 35% to $17. ...
BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.